Mary Bridget Waters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary Bridget Waters has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Lisa E. Manhart
Department of Epidemiology, University of Washington , Seattle, Washington
4 shared publications - Christine M. Khosropour
Department of Epidemiology, University of Washington, Seattle, USA
3 shared publications - Kristen M. Kreisel
Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
3 shared publications Christine M Khosropour
Department of Epidemiology, University of Washington , Seattle, Washington
2 shared publications- Kevin Hybiske
University of Washington
2 shared publications Ren Ikeda
Department of Medicine, University of Washington, Seattle, WA, USA
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Estimation of Antimicrobial-Resistant Mycoplasma genitalium Infections in People Aged 14–59 Years: Results From the National Health and Nutrition Examination Survey, United States, 2017–2018
Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessEstimation of Antimicrobial-Resistant Mycoplasma genitalium Infections in People Aged 14–59 Years: Results From the National Health and Nutrition Examination Survey, United States, 2017–2018
Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.
- Open Access
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Impact of Changes in Chlamydia Treatment Guidelines on Recurrent/Persistent Rectal Chlamydia trachomatis Infections
Introduction: Prior to 2021, the US Centers for Disease Control and Prevention (CDC) recommended either doxycycline or azithromycin as first-line treatments for Chlamydia trachomatis (CT). By 2016, there was evidence showing that doxycycline was more effective than azithromycin for the treatment of rectal CT. This motivated the Public Health—Seattle & King County Sexual Health Clinic to update their clinic's protocol to treat rectal CT with exclusively doxycycline in mid-2016. The CDC later recommended this in July 2021. Methods: Leveraging health records from the clinic, we performed a controlled interrupted time series analysis to evaluate the impact of updated treatment guidelines at the clinic on recurrent/persistent (RP) rectal chlamydia (RP-CT) infections among men who have sex with men using RP rectal gonorrhea (RP-GC) as a control outcome. We also evaluated if there were patient demographic and behavioral correlates associated with receipt of azithromycin before and after the change in clinic guidelines. Results: Our analysis revealed a significant relative trend change between RP-CT and RP-GC when comparing the period of full implementation to preimplementation, showing a 16.9% greater reduction in the quarterly trend of RP-CT cases compared to RP-GC cases. Self-identifying as White and with human immunodeficiency virus were positively associated with receiving azithromycin for treatment of rectal CT after the change in guidelines. Conclusions: The significant reduction in the trend change for RP-CT versus RP-GC when comparing the fully implemented period of exclusive doxycycline to the preimplementation period demonstrates the impact of the new treatment guidelines in reducing incidence of RP-CT infections.
- 1 August 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Open AccessImpact of Changes in Chlamydia Treatment Guidelines on Recurrent/Persistent Rectal Chlamydia trachomatis Infections
Introduction: Prior to 2021, the US Centers for Disease Control and Prevention (CDC) recommended either doxycycline or azithromycin as first-line treatments for Chlamydia trachomatis (CT). By 2016, there was evidence showing that doxycycline was more effective than azithromycin for the treatment of rectal CT. This motivated the Public Health—Seattle & King County Sexual Health Clinic to update their clinic's protocol to treat rectal CT with exclusively doxycycline in mid-2016. The CDC later recommended this in July 2021. Methods: Leveraging health records from the clinic, we performed a controlled interrupted time series analysis to evaluate the impact of updated treatment guidelines at the clinic on recurrent/persistent (RP) rectal chlamydia (RP-CT) infections among men who have sex with men using RP rectal gonorrhea (RP-GC) as a control outcome. We also evaluated if there were patient demographic and behavioral correlates associated with receipt of azithromycin before and after the change in clinic guidelines. Results: Our analysis revealed a significant relative trend change between RP-CT and RP-GC when comparing the period of full implementation to preimplementation, showing a 16.9% greater reduction in the quarterly trend of RP-CT cases compared to RP-GC cases. Self-identifying as White and with human immunodeficiency virus were positively associated with receiving azithromycin for treatment of rectal CT after the change in guidelines. Conclusions: The significant reduction in the trend change for RP-CT versus RP-GC when comparing the fully implemented period of exclusive doxycycline to the preimplementation period demonstrates the impact of the new treatment guidelines in reducing incidence of RP-CT infections.
- 24 December 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (6) , 325-332
Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013–2016
Objectives: Women who report sex with women are thought to have a lower risk of Chlamydia trachomatis (CT) infection than women who report sex with men only (WSM-only), but comparisons of lifetime burden are limited. Methods: Among 1418 sexually experienced women aged 18 to 39 years participating in the National Health and Nutrition Examination Survey (2013–2016), we estimated weighted CT seroprevalence and Wald-based 95% confidence intervals (CIs) in women who reported ever having sex with a woman (all reported having sex with men also) (WSWM) compared with WSM-only. We defined seropositivity as detection of Pgp3 antibodies and used stratified Poisson regression with robust standard errors to estimate prevalence ratios (PRs). Results: More than half (58.3%) were White non-Hispanic; 16.2% were WSWM. Women who had sex with women and men were somewhat younger (mean, 27.8 vs. 29.0 years; P = 0.07), were younger at sexual debut (mean, 15.6 vs. 17.5 years; P < 0.001), and had more lifetime male sexual partners (mean, 15.9 vs. 6.4; P < 0.001) than WSM-only. Weighted CT seroprevalence was 38.9% (95% CI, 30.4%–47.4%) in WSWM and 28.6% (95% CI, 24.4%–32.9%) in WSM-only. Correlates of higher CT seroprevalence in both groups were Black non-Hispanic race/ethnicity, Hispanic ethnicity, and CT infection in the prior year. Having ≥5 lifetime male partners compared with 1 to 2 partners was associated with higher seroprevalence among WSWM (PR, 4.5; 95% CI, 1.77–11.44) and WSM-only (PR, 2.7; 95% CI, 1.87–3.69). Among WSWM, bisexual identity was associated with lower seroprevalence. Among WSM-only, low income and younger age at sexual debut were associated with higher seroprevalence. Conclusion: Lifetime CT burden was higher in WSWM than WSM-only. Number of lifetime male partners was the strongest predictor of seropositivity for WSWM.
- 24 December 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (6) , 325-332
Comparison of Chlamydia trachomatis Seroprevalence and Risk Factors for Infection Among Women by Gender/Sex of Sex Partner, United States, 2013–2016
Objectives: Women who report sex with women are thought to have a lower risk of Chlamydia trachomatis (CT) infection than women who report sex with men only (WSM-only), but comparisons of lifetime burden are limited. Methods: Among 1418 sexually experienced women aged 18 to 39 years participating in the National Health and Nutrition Examination Survey (2013–2016), we estimated weighted CT seroprevalence and Wald-based 95% confidence intervals (CIs) in women who reported ever having sex with a woman (all reported having sex with men also) (WSWM) compared with WSM-only. We defined seropositivity as detection of Pgp3 antibodies and used stratified Poisson regression with robust standard errors to estimate prevalence ratios (PRs). Results: More than half (58.3%) were White non-Hispanic; 16.2% were WSWM. Women who had sex with women and men were somewhat younger (mean, 27.8 vs. 29.0 years; P = 0.07), were younger at sexual debut (mean, 15.6 vs. 17.5 years; P < 0.001), and had more lifetime male sexual partners (mean, 15.9 vs. 6.4; P < 0.001) than WSM-only. Weighted CT seroprevalence was 38.9% (95% CI, 30.4%–47.4%) in WSWM and 28.6% (95% CI, 24.4%–32.9%) in WSM-only. Correlates of higher CT seroprevalence in both groups were Black non-Hispanic race/ethnicity, Hispanic ethnicity, and CT infection in the prior year. Having ≥5 lifetime male partners compared with 1 to 2 partners was associated with higher seroprevalence among WSWM (PR, 4.5; 95% CI, 1.77–11.44) and WSM-only (PR, 2.7; 95% CI, 1.87–3.69). Among WSWM, bisexual identity was associated with lower seroprevalence. Among WSM-only, low income and younger age at sexual debut were associated with higher seroprevalence. Conclusion: Lifetime CT burden was higher in WSWM than WSM-only. Number of lifetime male partners was the strongest predictor of seropositivity for WSWM.
- 2 December 2024
- Published by CSIRO Publishing in Sexual Health
- Vol. 21 (6)
Comparison of IgG serum antibodies, electronic health records and self-report in estimating past infection with Chlamydia trachomatis in a cohort of men who have sex with men
Background: The best method for measuring a history of Chlamydia trachomatis (CT) infections is unknown. We examined the reliability of three methods as markers of past CT infections: IgG serum antibodies, the electronic health record (EHR) and self-report. Methods: This cross-sectional study used data from a cohort study of 122 MSM in King County, Washington, United States. Sera were tested for IgG using the mixed CT peptide enzyme-linked immunosorbent assay (ELISA). Participant data for past CT diagnoses were extracted from the EHR. Self-report of past CT was collected via survey. We calculated positive and negative percent agreements of CT history using total IgG serum antibodies to CT, past EHR diagnosis and self-report of past CT as reference measures when they were compared with one another. Results: Of those who were IgG seropositive, only 41.5% had a past diagnosis of CT in their EHRs, but 74.4% self-reported a history of CT. The majority (92.7%) of participants who had a diagnosis of CT in their EHRs reported a past CT infection. Conclusions: Self-report in combination with IgG serum antibodies to CT may be a more reliable indicator of past CT than EHRs in settings without comprehensive EHRs.
- 2 December 2024
- Published by CSIRO Publishing in Sexual Health
- Vol. 21 (6)
Comparison of IgG serum antibodies, electronic health records and self-report in estimating past infection with Chlamydia trachomatis in a cohort of men who have sex with men
Background: The best method for measuring a history of Chlamydia trachomatis (CT) infections is unknown. We examined the reliability of three methods as markers of past CT infections: IgG serum antibodies, the electronic health record (EHR) and self-report. Methods: This cross-sectional study used data from a cohort study of 122 MSM in King County, Washington, United States. Sera were tested for IgG using the mixed CT peptide enzyme-linked immunosorbent assay (ELISA). Participant data for past CT diagnoses were extracted from the EHR. Self-report of past CT was collected via survey. We calculated positive and negative percent agreements of CT history using total IgG serum antibodies to CT, past EHR diagnosis and self-report of past CT as reference measures when they were compared with one another. Results: Of those who were IgG seropositive, only 41.5% had a past diagnosis of CT in their EHRs, but 74.4% self-reported a history of CT. The majority (92.7%) of participants who had a diagnosis of CT in their EHRs reported a past CT infection. Conclusions: Self-report in combination with IgG serum antibodies to CT may be a more reliable indicator of past CT than EHRs in settings without comprehensive EHRs.
- 19 April 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (1) , 250-262
Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations
Chlamydia trachomatis (CT) is a sexually transmitted infection that can lead to adverse reproductive health outcomes. CT prevalence estimates are primarily derived from screening using nucleic acid amplification tests (NAATs). However, screening guidelines in the United States only include particular subpopulations, and NAATs only detect current infections. In contrast, seroassays identify past CT infections, which is important for understanding the public health impacts of CT, including pelvic inflammatory disease and tubal factor infertility. Older seroassays have been plagued by low sensitivity and specificity and have not been validated using a consistent reference measure, making it challenging to compare studies, define the epidemiology of CT, and determine the effectiveness of control programs. Newer seroassays have better performance characteristics. This narrative review summarizes the “state of the science” for CT seroassays that have been applied in epidemiologic studies and provides practical considerations for interpreting the literature and employing seroassays in future research.
- 19 April 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (1) , 250-262
Chlamydia trachomatis Seroassays Used in Epidemiologic Research: A Narrative Review and Practical Considerations
Chlamydia trachomatis (CT) is a sexually transmitted infection that can lead to adverse reproductive health outcomes. CT prevalence estimates are primarily derived from screening using nucleic acid amplification tests (NAATs). However, screening guidelines in the United States only include particular subpopulations, and NAATs only detect current infections. In contrast, seroassays identify past CT infections, which is important for understanding the public health impacts of CT, including pelvic inflammatory disease and tubal factor infertility. Older seroassays have been plagued by low sensitivity and specificity and have not been validated using a consistent reference measure, making it challenging to compare studies, define the epidemiology of CT, and determine the effectiveness of control programs. Newer seroassays have better performance characteristics. This narrative review summarizes the “state of the science” for CT seroassays that have been applied in epidemiologic studies and provides practical considerations for interpreting the literature and employing seroassays in future research.